Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder

Danthasinghe Waduge Badrajee Piyarathna, Thekkelnaycke M. Rajendiran, Vasanta Putluri, Venkatrao Vantaku, Tanu Soni, Friedrich Carl von Rundstedt, Sri Ramya Donepudi, Feng Jin, Suman Maity, Chandrashekar Ambati, Jianrong Dong, Daniel Gödde, Stephan Roth, Stephan Störkel, Stephan Degener, George Michailidis, Seth P. Lerner, Subramaniam Pennathur, Yair Lotan, Cristian Coarfa & 2 others Arun Sreekumar, Nagireddy Putluri

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The first global lipidomic profiles associated with urothelial cancer of the bladder (UCB) and its clinical stages associated with progression were identified. Objective: To identify lipidomic signatures associated with survival and different clinical stages of UCB. Design, setting, and participants: Pathologically confirmed 165 bladder-derived tissues (126 UCB, 39 benign adjacent or normal bladder tissues). UCB tissues included Ta (n = 16), T1 (n = 30), T2 (n = 43), T3 (n = 27), and T4 (n = 9); lymphovascular invasion (LVI) positive (n = 52) and negative (n = 69); and lymph node status N0 (n = 28), N1 (n = 11), N2 (n = 9), N3 (n = 3), and Nx (n = 75). Results and limitations: UCB tissues have higher levels of phospholipids and fatty acids, and reduced levels of triglycerides compared with benign tissues. A total of 59 genes associated with altered lipids in UCB strongly correlate with patient survival in an UCB public dataset. Within UCB, there was a progressive decrease in the levels of phosphatidylserine (PS), phosphatidylethanolamines (PEs), and phosphocholines, whereas an increase in the levels of diacylglycerols (DGs) with tumor stage. Transcript and protein expression of phosphatidylserine synthase 1, which converts DGs to PSs, decreased progressively with tumor stage. Levels of DGs and lyso-PEs were significantly elevated in tumors with LVI and lymph node involvement, respectively. Lack of carcinoma in situ and treatment information is the limitation of our study. Conclusions: To date, this is the first study describing the global lipidomic profiles associated with UCB and identifies lipids associated with tumor stages, LVI, and lymph node status. Our data suggest that triglycerides serve as the primary energy source in UCB, while phospholipid alterations could affect membrane structure and/or signaling associated with tumor progression. Patient summary: Lipidomic alterations identified in this study set the stage for characterization of pathways associated with these altered lipids that, in turn, could inform the development of first-of-its-kind lipid-based noninvasive biomarkers and novel therapeutic targets for aggressive urothelial cancer of the bladder. Altered lipid metabolism, particularly metabolism of phospholipids and triglycerides, in clinical stages of bladder cancer lays the framework for understanding the biological basis of progression of urothelial cancer of the bladder, development of innovative lipid-based noninvasive markers for disease prognosis, and novel therapeutic regimens targeting lipid pathways.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - 2017

Fingerprint

Urinary Bladder Neoplasms
Lipids
Diglycerides
Phosphatidylethanolamines
Phospholipids
Triglycerides
Lymph Nodes
Neoplasms
CDPdiacylglycerol-Serine O-Phosphatidyltransferase
Urinary Bladder
Phosphorylcholine
Survival
Phosphatidylserines
Carcinoma in Situ
Lipid Metabolism
Fatty Acids
Therapeutics
Biomarkers

Keywords

  • Lymphovascular invasion
  • Phosphatidylserine synthase
  • Phospholipids
  • Triglycerides

ASJC Scopus subject areas

  • Urology

Cite this

Piyarathna, D. W. B., Rajendiran, T. M., Putluri, V., Vantaku, V., Soni, T., von Rundstedt, F. C., ... Putluri, N. (Accepted/In press). Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. European Urology Focus. https://doi.org/10.1016/j.euf.2017.04.005

Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. / Piyarathna, Danthasinghe Waduge Badrajee; Rajendiran, Thekkelnaycke M.; Putluri, Vasanta; Vantaku, Venkatrao; Soni, Tanu; von Rundstedt, Friedrich Carl; Donepudi, Sri Ramya; Jin, Feng; Maity, Suman; Ambati, Chandrashekar; Dong, Jianrong; Gödde, Daniel; Roth, Stephan; Störkel, Stephan; Degener, Stephan; Michailidis, George; Lerner, Seth P.; Pennathur, Subramaniam; Lotan, Yair; Coarfa, Cristian; Sreekumar, Arun; Putluri, Nagireddy.

In: European Urology Focus, 2017.

Research output: Contribution to journalArticle

Piyarathna, DWB, Rajendiran, TM, Putluri, V, Vantaku, V, Soni, T, von Rundstedt, FC, Donepudi, SR, Jin, F, Maity, S, Ambati, C, Dong, J, Gödde, D, Roth, S, Störkel, S, Degener, S, Michailidis, G, Lerner, SP, Pennathur, S, Lotan, Y, Coarfa, C, Sreekumar, A & Putluri, N 2017, 'Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder', European Urology Focus. https://doi.org/10.1016/j.euf.2017.04.005
Piyarathna, Danthasinghe Waduge Badrajee ; Rajendiran, Thekkelnaycke M. ; Putluri, Vasanta ; Vantaku, Venkatrao ; Soni, Tanu ; von Rundstedt, Friedrich Carl ; Donepudi, Sri Ramya ; Jin, Feng ; Maity, Suman ; Ambati, Chandrashekar ; Dong, Jianrong ; Gödde, Daniel ; Roth, Stephan ; Störkel, Stephan ; Degener, Stephan ; Michailidis, George ; Lerner, Seth P. ; Pennathur, Subramaniam ; Lotan, Yair ; Coarfa, Cristian ; Sreekumar, Arun ; Putluri, Nagireddy. / Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. In: European Urology Focus. 2017.
@article{f09b4fe6be7140f48b9b5e592b3fda50,
title = "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder",
abstract = "Background: The first global lipidomic profiles associated with urothelial cancer of the bladder (UCB) and its clinical stages associated with progression were identified. Objective: To identify lipidomic signatures associated with survival and different clinical stages of UCB. Design, setting, and participants: Pathologically confirmed 165 bladder-derived tissues (126 UCB, 39 benign adjacent or normal bladder tissues). UCB tissues included Ta (n = 16), T1 (n = 30), T2 (n = 43), T3 (n = 27), and T4 (n = 9); lymphovascular invasion (LVI) positive (n = 52) and negative (n = 69); and lymph node status N0 (n = 28), N1 (n = 11), N2 (n = 9), N3 (n = 3), and Nx (n = 75). Results and limitations: UCB tissues have higher levels of phospholipids and fatty acids, and reduced levels of triglycerides compared with benign tissues. A total of 59 genes associated with altered lipids in UCB strongly correlate with patient survival in an UCB public dataset. Within UCB, there was a progressive decrease in the levels of phosphatidylserine (PS), phosphatidylethanolamines (PEs), and phosphocholines, whereas an increase in the levels of diacylglycerols (DGs) with tumor stage. Transcript and protein expression of phosphatidylserine synthase 1, which converts DGs to PSs, decreased progressively with tumor stage. Levels of DGs and lyso-PEs were significantly elevated in tumors with LVI and lymph node involvement, respectively. Lack of carcinoma in situ and treatment information is the limitation of our study. Conclusions: To date, this is the first study describing the global lipidomic profiles associated with UCB and identifies lipids associated with tumor stages, LVI, and lymph node status. Our data suggest that triglycerides serve as the primary energy source in UCB, while phospholipid alterations could affect membrane structure and/or signaling associated with tumor progression. Patient summary: Lipidomic alterations identified in this study set the stage for characterization of pathways associated with these altered lipids that, in turn, could inform the development of first-of-its-kind lipid-based noninvasive biomarkers and novel therapeutic targets for aggressive urothelial cancer of the bladder. Altered lipid metabolism, particularly metabolism of phospholipids and triglycerides, in clinical stages of bladder cancer lays the framework for understanding the biological basis of progression of urothelial cancer of the bladder, development of innovative lipid-based noninvasive markers for disease prognosis, and novel therapeutic regimens targeting lipid pathways.",
keywords = "Lymphovascular invasion, Phosphatidylserine synthase, Phospholipids, Triglycerides",
author = "Piyarathna, {Danthasinghe Waduge Badrajee} and Rajendiran, {Thekkelnaycke M.} and Vasanta Putluri and Venkatrao Vantaku and Tanu Soni and {von Rundstedt}, {Friedrich Carl} and Donepudi, {Sri Ramya} and Feng Jin and Suman Maity and Chandrashekar Ambati and Jianrong Dong and Daniel G{\"o}dde and Stephan Roth and Stephan St{\"o}rkel and Stephan Degener and George Michailidis and Lerner, {Seth P.} and Subramaniam Pennathur and Yair Lotan and Cristian Coarfa and Arun Sreekumar and Nagireddy Putluri",
year = "2017",
doi = "10.1016/j.euf.2017.04.005",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder

AU - Piyarathna, Danthasinghe Waduge Badrajee

AU - Rajendiran, Thekkelnaycke M.

AU - Putluri, Vasanta

AU - Vantaku, Venkatrao

AU - Soni, Tanu

AU - von Rundstedt, Friedrich Carl

AU - Donepudi, Sri Ramya

AU - Jin, Feng

AU - Maity, Suman

AU - Ambati, Chandrashekar

AU - Dong, Jianrong

AU - Gödde, Daniel

AU - Roth, Stephan

AU - Störkel, Stephan

AU - Degener, Stephan

AU - Michailidis, George

AU - Lerner, Seth P.

AU - Pennathur, Subramaniam

AU - Lotan, Yair

AU - Coarfa, Cristian

AU - Sreekumar, Arun

AU - Putluri, Nagireddy

PY - 2017

Y1 - 2017

N2 - Background: The first global lipidomic profiles associated with urothelial cancer of the bladder (UCB) and its clinical stages associated with progression were identified. Objective: To identify lipidomic signatures associated with survival and different clinical stages of UCB. Design, setting, and participants: Pathologically confirmed 165 bladder-derived tissues (126 UCB, 39 benign adjacent or normal bladder tissues). UCB tissues included Ta (n = 16), T1 (n = 30), T2 (n = 43), T3 (n = 27), and T4 (n = 9); lymphovascular invasion (LVI) positive (n = 52) and negative (n = 69); and lymph node status N0 (n = 28), N1 (n = 11), N2 (n = 9), N3 (n = 3), and Nx (n = 75). Results and limitations: UCB tissues have higher levels of phospholipids and fatty acids, and reduced levels of triglycerides compared with benign tissues. A total of 59 genes associated with altered lipids in UCB strongly correlate with patient survival in an UCB public dataset. Within UCB, there was a progressive decrease in the levels of phosphatidylserine (PS), phosphatidylethanolamines (PEs), and phosphocholines, whereas an increase in the levels of diacylglycerols (DGs) with tumor stage. Transcript and protein expression of phosphatidylserine synthase 1, which converts DGs to PSs, decreased progressively with tumor stage. Levels of DGs and lyso-PEs were significantly elevated in tumors with LVI and lymph node involvement, respectively. Lack of carcinoma in situ and treatment information is the limitation of our study. Conclusions: To date, this is the first study describing the global lipidomic profiles associated with UCB and identifies lipids associated with tumor stages, LVI, and lymph node status. Our data suggest that triglycerides serve as the primary energy source in UCB, while phospholipid alterations could affect membrane structure and/or signaling associated with tumor progression. Patient summary: Lipidomic alterations identified in this study set the stage for characterization of pathways associated with these altered lipids that, in turn, could inform the development of first-of-its-kind lipid-based noninvasive biomarkers and novel therapeutic targets for aggressive urothelial cancer of the bladder. Altered lipid metabolism, particularly metabolism of phospholipids and triglycerides, in clinical stages of bladder cancer lays the framework for understanding the biological basis of progression of urothelial cancer of the bladder, development of innovative lipid-based noninvasive markers for disease prognosis, and novel therapeutic regimens targeting lipid pathways.

AB - Background: The first global lipidomic profiles associated with urothelial cancer of the bladder (UCB) and its clinical stages associated with progression were identified. Objective: To identify lipidomic signatures associated with survival and different clinical stages of UCB. Design, setting, and participants: Pathologically confirmed 165 bladder-derived tissues (126 UCB, 39 benign adjacent or normal bladder tissues). UCB tissues included Ta (n = 16), T1 (n = 30), T2 (n = 43), T3 (n = 27), and T4 (n = 9); lymphovascular invasion (LVI) positive (n = 52) and negative (n = 69); and lymph node status N0 (n = 28), N1 (n = 11), N2 (n = 9), N3 (n = 3), and Nx (n = 75). Results and limitations: UCB tissues have higher levels of phospholipids and fatty acids, and reduced levels of triglycerides compared with benign tissues. A total of 59 genes associated with altered lipids in UCB strongly correlate with patient survival in an UCB public dataset. Within UCB, there was a progressive decrease in the levels of phosphatidylserine (PS), phosphatidylethanolamines (PEs), and phosphocholines, whereas an increase in the levels of diacylglycerols (DGs) with tumor stage. Transcript and protein expression of phosphatidylserine synthase 1, which converts DGs to PSs, decreased progressively with tumor stage. Levels of DGs and lyso-PEs were significantly elevated in tumors with LVI and lymph node involvement, respectively. Lack of carcinoma in situ and treatment information is the limitation of our study. Conclusions: To date, this is the first study describing the global lipidomic profiles associated with UCB and identifies lipids associated with tumor stages, LVI, and lymph node status. Our data suggest that triglycerides serve as the primary energy source in UCB, while phospholipid alterations could affect membrane structure and/or signaling associated with tumor progression. Patient summary: Lipidomic alterations identified in this study set the stage for characterization of pathways associated with these altered lipids that, in turn, could inform the development of first-of-its-kind lipid-based noninvasive biomarkers and novel therapeutic targets for aggressive urothelial cancer of the bladder. Altered lipid metabolism, particularly metabolism of phospholipids and triglycerides, in clinical stages of bladder cancer lays the framework for understanding the biological basis of progression of urothelial cancer of the bladder, development of innovative lipid-based noninvasive markers for disease prognosis, and novel therapeutic regimens targeting lipid pathways.

KW - Lymphovascular invasion

KW - Phosphatidylserine synthase

KW - Phospholipids

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=85018638489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018638489&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2017.04.005

DO - 10.1016/j.euf.2017.04.005

M3 - Article

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -